未知生产厂商
N4-Hydroxycytidine is a cytidine analog being investigated to treat COVID-19.
N4-Hydroxycytidine is a cytidine analog being investigated to treat COVID-19.
N4-hydroxycytidine is phosphorylated in tissue to the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations, known as viral error catastrophe. A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.
N4-hydroxycytidine and its prodrug EIDD-2801 is being studied for its activity against a number of viral infections including influenza, MERS-CoV, and SARS-CoV-2.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
